RELATING TO HEALTH.

SB 967 requires Medicaid and private health insurance plans to cover intravenous ketamine therapy for treating depression. The bill mandates this coverage for eligible patients and allocates state funding to support the program. It directly affects individuals seeking this specific depression treatment and insurers who must now include it in covered services. The policy change creates a new requirement for health coverage without specifying additional eligibility criteria beyond the therapy's use for depression.